OBJECTIVE: The prevalence of vitamin D inadequacy is high in obese individuals. Determining the response of serum 25-hydroxyvitamin D (25[OH]D) to vitamin D3 supplementation in obese and nonobese individuals may lead to concurrent recommendations for optimal vitamin D intake in these populations. The objective of this study was to determine the dose response of vitamin D3 in subjects with a body mass index ≥35 kg/m2. METHODS: Randomized, double-blind, placebo-controlled study. This study is an extension of our previous study of vitamin D dosing in healthy adults. After an assessment of baseline 25(OH)D levels, participants were randomized to a vitamin D supplementation arm (100 μg daily if baseline 25[OH]D was <50 nmol/L, or 50 μg daily if baseline 25[OH]D was ≥50 nmol/L) or placebo arm. Subjects with baseline 25(OH)D level ≥80 nmol/L were excluded from the study. Two months following randomization, a repeat 25(OH)D measurement was done. RESULTS: Final analysis included 25 subjects (14 placebo, 11 active). At 2 months, serum 25(OH)D concentration increased to a mean of 75 nmol/L in the active group. Mean slope (i.e., vitamin D3 response), defined as 25(OH) D change/baseline dose, was 0.398 nmol/L/μg/day. CONCLUSION: The dose response of vitamin D3 (slope) in obese subjects was significantly lower (P<.03) at 0.398 nmol/L/μg/day compared to the slope in the previous study of healthy subjects (0.66 nmol/L/μg/day). These results suggest that obese individuals may require 40% higher vitamin D intake than nonobese individuals to attain the same serum 25(OH)D concentration.
RCT Entities:
OBJECTIVE: The prevalence of vitamin D inadequacy is high in obese individuals. Determining the response of serum 25-hydroxyvitamin D (25[OH]D) to vitamin D3 supplementation in obese and nonobese individuals may lead to concurrent recommendations for optimal vitamin D intake in these populations. The objective of this study was to determine the dose response of vitamin D3 in subjects with a body mass index ≥35 kg/m2. METHODS: Randomized, double-blind, placebo-controlled study. This study is an extension of our previous study of vitamin D dosing in healthy adults. After an assessment of baseline 25(OH)D levels, participants were randomized to a vitamin D supplementation arm (100 μg daily if baseline 25[OH]D was <50 nmol/L, or 50 μg daily if baseline 25[OH]D was ≥50 nmol/L) or placebo arm. Subjects with baseline 25(OH)D level ≥80 nmol/L were excluded from the study. Two months following randomization, a repeat 25(OH)D measurement was done. RESULTS: Final analysis included 25 subjects (14 placebo, 11 active). At 2 months, serum 25(OH)D concentration increased to a mean of 75 nmol/L in the active group. Mean slope (i.e., vitamin D3 response), defined as 25(OH) D change/baseline dose, was 0.398 nmol/L/μg/day. CONCLUSION: The dose response of vitamin D3 (slope) in obese subjects was significantly lower (P<.03) at 0.398 nmol/L/μg/day compared to the slope in the previous study of healthy subjects (0.66 nmol/L/μg/day). These results suggest that obese individuals may require 40% higher vitamin D intake than nonobese individuals to attain the same serum 25(OH)D concentration.
Authors: L C Pop; D Sukumar; S H Schneider; Y Schlussel; T Stahl; C Gordon; X Wang; T V Papathomas; S A Shapses Journal: Osteoporos Int Date: 2016-08-17 Impact factor: 4.507
Authors: Spyridon N Karras; Stergios A Polyzos; Danforth A Newton; Carol L Wagner; Bruce W Hollis; Jody van den Ouweland; Erdinc Dursun; Duygu Gezen-Ak; Kalliopi Kotsa; Cedric Annweiler; Declan P Naughton Journal: Endocrine Date: 2017-11-18 Impact factor: 3.633
Authors: Jennifer L Jackson; Suzanne E Judd; Bhupesh Panwar; Virginia J Howard; Virginia G Wadley; Nancy S Jenny; Orlando M Gutiérrez Journal: J Clin Transl Endocrinol Date: 2016-09
Authors: L John Hoffer; Line Robitaille; Nelda Swinton; Jason Agulnik; Victor Cohen; David Small; Carmela Pepe; Shaun Eintracht Journal: Nutr J Date: 2016-10-06 Impact factor: 3.271
Authors: Daniel M McCartney; Paula M O'Shea; John L Faul; Martin J Healy; Greg Byrne; Tomás P Griffin; James Bernard Walsh; Declan G Byrne; Rose Anne Kenny Journal: Ir J Med Sci Date: 2020-11-21 Impact factor: 2.089